eISSN: 2449-9315
ISSN: 1234-8279
Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
2/2020
vol. 36
 
Share:
Share:
abstract:
Case report

A severe course of the COVID-19 in a patient receiving prophylactically lithium

Karolina Gattner
1
,
Janusz Rybakowski
2

  1. Centrum Psychiatryczne Szpitala HCP w Poznaniu
  2. Klinika Psychiatrii Dorosłych, Uniwersytet Medyczny w Poznaniu
Farmakoterapia w Psychiatrii i Neurologii 2020, 36 (2), 143–148
Online publish date: 2021/12/06
View full text Get citation
 
Introduction
The SARS-CoV2 pandemic makes a chal lenge for patients with bipolar disorder receiving prophy lactically lithium. There have been findings pointing to the antiviral effect of lithium which arouse suppositions that using the drug may prevent or attenuate the illness

Case report
A 58-year old male patient, inhabitant of Lombardy, with bipolar disorder for more than 20 years, who have been receiving prophylactically lithi um and valproate since 2010. In February 2020, became infected with COVID-19 disease, with a temperature of 40°C; chest pain, dyspnoea, and dry cough developed. SARS-CoV2 infection was confirmed by PCR test; chest imaging showed characteristic changes for the infection. He was treated with antibiotics, oxygen, fluids, and an tipyretic drugs. Hyperpyrexia and respiratory problems persisted for 40 day; full recovery occurred after 7 weeks.

Comments
This case shows that also in patients on long term lithium therapy, COVID-19 may run a severe course.

keywords:

SARS -CoV2, COVID-19, lithium, antiviral activity


Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.